Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate

Journal of Viral Hepatitis

Volumn 22, Issue 12, 2015, Pages 1079-1087

  Papatheodoridis, G ^a   Triantos, C ^b   Hadziyannis, E ^a   Zisimopoulos, K ^b   Georgiou, A ^a   Voulgaris, T ^a   Vlachogiannakos, I ^a   Nikolopoulou, V ^b   Manolakopoulos, S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

HBsAg; hepatitis B; interferon inducible protein 10; tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; TENOFOVIR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ANTIGEN DETECTION; ARTICLE; CHRONIC HEPATITIS B; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ELASTOGRAPHY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; BLOOD; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED;

ANTIVIRAL AGENTS; CHEMOKINE CXCL10; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TENOFOVIR;

EID: 84945473249     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12434     Document Type: Article

References (35)

1. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ,. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8: 167-178.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
3. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
4. Papatheodoridis GV,. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Liver Int 2013; 33 (Suppl. 1): 151-156.
5. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E,. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143: 629-636.
6. Suh SJ, Yeon JE, Yoon EL, et al,. Quantification of hepatitis B surface antigen as a predictor of off-treatment sustained virological response in chronic hepatitis B patients treated with oral nucleos(t)ide analogue. J Hepatol 2012; 56 (Suppl. 2): S191.
7. Jiang JN, Huang XH, Liang YX, et al,. The value of serum HBsAg levels in the prediction of relapse in the CHB patients who met NAs endpoint criteria. J Hepatol 2012; 56 (Suppl. 2): S205.
8. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ,. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.
9. Reijnders JG, Rijckborst V, Sonneveld MJ, et al,. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-454.
10. Fung J, Lai CL, Young J, et al,. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011; 106: 1766-1773.
11. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL,. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204: 415-418.
12. Papatheodoridis G, Goulis J, Manolakopoulos S, et al,. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol 2014; 60: 62-68.
13. Jaroszewicz J, Ho H, Markova A, et al,. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011; 16: 915-924.
14. Paraskevis D, Haida C, Tassopoulos N, et al,. Development and assessment of a novel real-time PCR assay quantitation of HBV-DNA. J Virol Methods 2002; 103: 201-212.
15. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
16. Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky J-M,. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013; 58: 676-683.
17. Neville LF, Mathiak G, Bagasra O,. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8: 207-219.
18. Narumi S, Tominaga Y, Tamaru M, et al,. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997; 158: 5536-5544.
19. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH,. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163: 6236-6243.
20. Lutgehetmann M, Bornscheuer T, Volz T, et al,. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011; 140: 2074-2083.
21. Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B,. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology 2010; 215: 113-123.
22. Mohit E, Bolhassani A, Zahedifard F, et al,. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. Mol Immunol 2013; 53: 149-160.
23. Brunetto MR, Moriconi F, Bonino F, et al,. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
24. Lai H, Peng C, Su W, et al,. Predictors of serum HBsAg decline in chronic hepatitis B patients undergoing entecavir therapy. Hepatology 2012; 56 (Suppl.): 396A.
25. Boglione L, D'Avolio A, Cariti G, et al,. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. Liver Int 2013; 33: 580-585.
26. Sugiyama M, Tanaka Y, Kato T, et al,. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44: 915-924.
27. Fylaktou A, Papaventsis D, Daoudaki M, Moskophidis M, Reiberger T, Malisiovas N,. Molecular epidemiology of chronic hepatitis B virus infection in Greece. J Med Virol 2011; 83: 245-252.
28. Chan HL, Buti M, Marcellin P, et al,. Comparison of serum HBsAg declines during tenofovir disoproxil fumarate (TDF) treatment in different chronic hepatitis B (CHB) sub-populations. J Hepatol 2013; 58 (Suppl. 1): S309.
29. Papatheodoridis GV, Goulis I, Manolakopoulos S, et al,. Changes of serum HBsAg levels in HBeAg-negative chronic hepatitis B patients under long-term therapy with nucleos(t)ide analogue(s). Hepatology 2011; 54 (Suppl.): 1054A.
30. Karayiannis P,. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003; 51: 761-785.
31. Chan HLY, Wong GL, Lo AO, Chiim AM, Chan H-Y, Wong VW,. Early on-treatment decline of serum hepatitis B surface antigen (HBsAg) is associated with faster subsequent HBsAg reduction in HBeAg-negative chronic hepatitis B. J Hepatol 2012; 56 (Suppl. 2): S199.
32. Seto WK, Hui AJ, Wong VW, et al,. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 2015; 64: 667-672.
33. Chan HL, Thompson A, Martinot-Peignoux M, et al,. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011; 55: 1121-1131.
34. Mangia G, Lampertico P, Invernizzi F, et al,. Serum HBsAg decline is faster than previously estimated in long-term NUC responders with low treatment-induced HBsAg levels. J Hepatol 2013; 58 (Suppl. 1): S307.
35. Marcellin P, Ahn SH, Ma X, et al,. HBsAg loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trial. Hepatology 2014; 60 (Suppl.): 294A.